This website uses cookies to ensure you get the best experience on our website.
- Table of Contents
Source-linked RAD51B Western blot protocol options, expected-band and isoform facts, troubleshooting for weak or shifted signal, and recommended anti-RAD51B WB antibodies. Everything you need to plan the experiment before you commit precious samples.
Expected bands, source-linked protocol options, controls and antibodies — the at-a-glance facts below, then the full design guide.
| Expected band | ~42.2 kDa | |
| Gel | 12–15% (standard starting point) | |
| Positive control | Adrenal gland (IHC candidate; verify WB) +4 more | |
| Negative control | Suggested KO / knockdown lysate |
| PTM | Phosphorylated | |
| Caveat | Phosphorylation-state controls | |
| Gene-set association | MSigDB C7 membership | |
| Isoform | 5 isoform(s) |
The A20019 protocol combines labelled catalog values with standard starting conditions. Published comparisons retain their own sample, reagent and detection scope.
| Sample / lysate | lysates from COS7 cells, (catalog A20019) |
| Gel % | 12–15% (standard starting point) |
| Load | 20–30 µg total protein per lane; optimize for abundance (standard starting point) |
| Transfer | Standard semi-dry transfer; verify efficiency (standard starting point) |
| Membrane | 0.45 µm PVDF (standard starting point) |
| Blocking | the synthesized peptide (catalog A20019) |
| Primary antibody | A20019; use the WB datasheet starting dilution (standard starting point) |
| Primary incubation | Overnight at 4 °C (standard starting point) |
| Secondary antibody | Species-matched HRP conjugate at validated dilution (standard starting point) |
| Secondary incubation | 1 h at room temperature (standard starting point) |
| Wash | 3 × 5 min in TBST (standard starting point) |
| Detection | ECL; bracket exposures to avoid saturation (standard starting point) |
RAD51B is predicted at 42.2 kDa; five isoforms could affect band patterns, but distinct migration has not been demonstrated.
| Band near 42.2 kDa | Consistent with the predicted RAD51B size; confirm identity with controls |
| Two bands at different positions | Could reflect splice isoforms; their migration is not established |
| Several bands at different positions | Could reflect the five annotated isoforms; confirm each band’s identity |
| Stronger band in a nuclear fraction | Consistent with RAD51B’s nuclear location |
| UniProt predicted mass | Places the predicted protein near 42.2 kDa |
| Splice isoform 1 | Its individual mass and migration are not supplied |
| Splice isoform 2 | May differ in size; its migration is not established |
| Splice isoform 3 | May differ in size; its migration is not established |
| Splice isoform 4 | May differ in size; its migration is not established |
| Splice isoform 5 | May differ in size; its migration is not established |
| Situation | Likely cause | Next action |
|---|---|---|
| No band in lysate | Nuclear RAD51B may be dilute in whole-cell lysate | Check a nuclear fraction and a positive control |
| Multiple bands | RAD51B has five annotated splice isoforms, but their migration is unknown | Use knockdown and isoform-aware controls to identify bands |
| Band higher than expected | No listed modification establishes a higher apparent mass | Check band identity with knockdown and an independent antibody |
| Band lower than expected | An isoform is possible, but no isoform-specific mass is supplied | Check band identity and antibody epitope coverage |
| Weak or no signal | Nuclear RAD51B may be underrepresented in the sample | Verify loading and enrich the nuclear fraction |
Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adrenal gland | glandular cells | High | Protein (IHC) | HPA → |
| Appendix | glandular cells | High | Protein (IHC) | HPA → |
| Bone marrow | hematopoietic cells | High | Protein (IHC) | HPA → |
| Breast | glandular cells | High | Protein (IHC) | HPA → |
| Bronchus | respiratory epithelial cells | High | Protein (IHC) | HPA → |
| Tissue | Cell type | Level | Evidence | Source |
|---|---|---|---|---|
| Adipose tissue | adipocytes | Medium | Protein (IHC) | HPA → |
| Heart muscle | cardiomyocytes | Medium | Protein (IHC) | HPA → |
| Prostate | glandular cells | Medium | Protein (IHC) | HPA → |
| Vagina | squamous epithelial cells | Medium | Protein (IHC) | HPA → |
| Adrenal gland | glandular cells | High | Protein (IHC) | HPA → |
Deeper troubleshooting and optimisation questions for RAD51B, answered from its protein features.
Catalog antibodies with Western blot application and product-specific WB images. Evaluate suitability with the reported sample, controls and experimental conditions.
Two the supplier anti-RAD51B antibodies have WB images: A20019 in COS7 lysate with a peptide-blocked lane, and A02658-2 in three human cell lysates with a reported ~42 kDa band. These examples do not establish performance across all listed reactive species or sample types.
Which to pick: For human cell lysates, A02658-2 has documented WB results in Jurkat, HaCaT and U2OS samples. A20019 lists human, monkey and mouse reactivity, with a COS7 WB image and peptide-blocked lane; the supplied evidence does not show WB results for every listed species.